RecruitingPhase 2/3

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

United States176 participantsStarted 2025-09-30

Plain-language summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria: • Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility Key Exclusion Criteria: • Hypersensitivity to investigational medicinal product or to any of its excipients Other protocol defined Inclusion/Exclusion criteria will apply

What they're measuring

Proportion of Participants with Complete Clinical Remission Definition 1 (CR1)

Timeframe: At Week 104

Trial details

NCT IDNCT07204275

SponsorVertex Pharmaceuticals Incorporated

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-12-29

Contact for this trial

Medical Information

617-341-6777 medicalinfo@vrtx.com

View on ClinicalTrials.gov More Primary Membranous Nephropathy trials